TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17630036

Group type: EXPERIMENTAL
Intervention: Combination treatment (capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Sequential treatment (capecitabine, irinotecan, and capecitabine plus oxaliplatin)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 820
Study: 15450049

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) oral suspension 800 mg/d for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 0
Study: 11876454

Group type: EXPERIMENTAL
Intervention: Parental education and use of parents as nursing assistants on ward A
Number of subjects: 1081

Group type: COMPARATOR
Intervention: No parental assistance on ward B
Number of subjects: 1081
Study: 9715363

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clomipramine (open maintenance treatment)
Number of subjects: 8
Study: 8071282

Group type: EXPERIMENTAL
Intervention: Dothiepin (150 mg nightly)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Doxepin (150 mg nightly)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 579
Study: 3195222

Group type: EXPERIMENTAL
Intervention: First series (12 persons) with short clicks; intervals increased from 100 to 500 ms, decreased from 5000 to 100 ms, or varied randomly.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Second series (24 persons) with short clicks; only regime 3 applied (random order).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Third series (6 persons) with electrocutaneous stimuli; intervals increased from 100 to 500 ms, decreased from 5000 to 100 ms, or varied randomly.
Number of subjects: 42
Study: 786358

Group type: EXPERIMENTAL
Intervention: Single daily dose of phenytoin sodium at 12.00 hours
Number of subjects: 53

Group type: COMPARATOR
Intervention: Two or three spaced doses of phenytoin sodium/day
Number of subjects: 53
Study: 30700230

Group type: EXPERIMENTAL
Intervention: COPD Web in addition to usual care (n=43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care alone (control group, n=40)
Number of subjects: 83
Study: 28551844

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg on day 1 followed by 100 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 47
Study: 25307530

Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal-weight women
Number of subjects: 105
Study: 24022373

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 21967830

Group type: EXPERIMENTAL
Intervention: Physician-level incentive
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Group-level incentive
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Combination of physician and group incentives
Number of subjects: 125

Group type: COMPARATOR
Intervention: No incentives (control)
Number of subjects: 125
Study: 19757980

Group type: EXPERIMENTAL
Intervention: Acupressure therapy (AT)
Number of subjects: 80
Study: 17694378

Group type: EXPERIMENTAL
Intervention: Combined intraarterial and intramuscular transplantation of autologous mononuclear bone marrow stem cells
Number of subjects: 13
Study: 15093755

Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel antagonists (nifedipine or nicardipine)
Number of subjects: 42
Study: 11210250

Group type: EXPERIMENTAL
Intervention: ENDOflash rotary files
Number of subjects: 24

Group type: COMPARATOR
Intervention: ProFile files (.04, .06 and Orifice Shapers)
Number of subjects: 24
Study: 11367652

Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Complex Ester Tablet (TWT), 2 tablets, 3 times a day for 6 weeks
Number of subjects: 277

Group type: COMPARATOR
Intervention: Tripterygium Wilfordii Polycoside Tablet (TPT), 2 tablets, 3 times a day for 6 weeks
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Complex Ester Tablet (TWT)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Tripterygium Wilfordii Polycoside Tablet (TPT)
Number of subjects: 277
Study: 7889947

Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg single intravenous dose)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Cefamandole (2 g before and 1 g after surgery)
Number of subjects: 496
Study: 3053896

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 8
Study: 29254510

Group type: EXPERIMENTAL
Intervention: Post-deployment family violence
Number of subjects: 6711

Group type: EXPERIMENTAL
Intervention: Post-deployment stranger violence
Number of subjects: 6711

Group type: EXPERIMENTAL
Intervention: Combat role deployment
Number of subjects: 6711

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder symptoms
Number of subjects: 6711

Group type: EXPERIMENTAL
Intervention: Common mental disorders
Number of subjects: 6711

Group type: EXPERIMENTAL
Intervention: Aggression
Number of subjects: 6711
Study: 29144393

Group type: EXPERIMENTAL
Intervention: HWP‐F (hydrolyzed whey/intact casein =63/37)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IWP‐F (intact whey/intact casein =61/39)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BF (breast-fed)
Number of subjects: 0
Study: 26847031

Group type: EXPERIMENTAL
Intervention: Peer support group attendance (8 weekly sessions of 2 hours each)
Number of subjects: 33
Study: 24184274

Group type: EXPERIMENTAL
Intervention: BR+Ex (combined aerobic and resistive exercises)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BR+Nut (nutritional leucine and valine diet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BR (bed rest only)
Number of subjects: 0
Study: 21397126

Group type: EXPERIMENTAL
Intervention: Follow-up telephone calls to patients after discharge
Number of subjects: 50
Study: 19274316

Group type: EXPERIMENTAL
Intervention: 1 mg (1 ml) of morphine diluted in 9 ml of saline
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 25 mg (10 ml) of 0.25% bupivacaine without epinephrine
Number of subjects: 39
Study: 17370787

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 1.5 mg/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nalbuphine 0.1 mg/kg
Number of subjects: 70
Study: 12655910

Group type: EXPERIMENTAL
Intervention: Telephone-based peer support (initiated within 48 to 72 hours of randomization) from a trained mother who previously experienced PPD.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard community postpartum care (control group).
Number of subjects: 42
Study: 10734596

Group type: EXPERIMENTAL
Intervention: Early water contact with or without shower foam from the second postoperative day
Number of subjects: 817

Group type: COMPARATOR
Intervention: Wounds kept dry until stitches were removed
Number of subjects: 817
Study: 8882904

Group type: COMPARATOR
Intervention: V0.1-rest in normal subjects (Nor: 0.25 +/- 0.10 l/s), CPE (0.27 +/- 0.06 l/s), IP (0.26 +/- 0.06 l/s)
Number of subjects: 15

Group type: COMPARATOR
Intervention: P0.1-rest in normal subjects (Nor: 1.98 +/- 0.61 hPa), CPE (3.00 +/- 0.80 hPa), IP (3.60 +/- 0.68 hPa)
Number of subjects: 15

Group type: COMPARATOR
Intervention: V0.1-max in normal subjects (Nor: 3.66 +/- 1.16 l/s), CPE (0.82 +/- 0.25 l/s), IP (1.02 +/- 0.21 l/s)
Number of subjects: 15

Group type: COMPARATOR
Intervention: P0.1-max in normal subjects (Nor: 33.2 +/- 10.2 hPa), CPE (9.8 +/- 3.7 hPa), IP (19.5 +/- 3.4 hPa)
Number of subjects: 15
Study: 1607430

Group type: EXPERIMENTAL
Intervention: Amalgam core build-up
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Composite core build-up
Number of subjects: 87
Study: 3884032

Group type: EXPERIMENTAL
Intervention: Conventional superficial X-ray therapy (300 rad, 3 Gy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Grenz ray therapy (900 rad, 9 Gy)
Number of subjects: 25
Study: 30203866

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotonic exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 20
Study: 26778191

Group type: EXPERIMENTAL
Intervention: Texture analysis based on T1-weighted MRI
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Texture analysis based on T2-weighted MRI
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Texture analysis based on diffusion-weighted MRI
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Supervised learning models based on T1 sequence
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Supervised learning models based on T2 W
Number of subjects: 53

Group type: COMPARATOR
Intervention: Comparison of two classifiers
Number of subjects: 53
Study: 24861886

Group type: EXPERIMENTAL
Intervention: Delphinol® (maqui berry extract)
Number of subjects: 10
Study: 22017365

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite extract for 2 years
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) and Placebo
Number of subjects: 251
Study: 20636999

Group type: EXPERIMENTAL
Intervention: Cream B (cosmetic emulsion with active ingredients: soy and jasmine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cream A (vehicle without active ingredients)
Number of subjects: 24
Study: 18569241

Group type: EXPERIMENTAL
Intervention: Computer programs with teacher-led presentation
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Combination of computer programs and teacher-led presentation
Number of subjects: 871

Group type: COMPARATOR
Intervention: Teacher-led presentation
Number of subjects: 871
Study: 16055571

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 one-hour sessions per week)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (weekly relaxation and focus group discussions)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 92
Study: 12448352

Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin (0.4 mumol/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin (2 mumol/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin (10 mumol/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 10598433

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine/bupivacaine (25 ml of 0.25% bupivacaine and 2 mg of morphine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of diclofenac i.m. (75 mg) and intraarticular morphine/bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diclofenac i.m. (75 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8564134

Group type: EXPERIMENTAL
Intervention: auto-CPAP (Morphée Plus)
Number of subjects: 16

Group type: COMPARATOR
Intervention: constant-CPAP (Morphée Plus)
Number of subjects: 16
Study: 1752623

Group type: EXPERIMENTAL
Intervention: Twice a day long acting sustained release isosorbide dinitrate (SRISDN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Four times daily short acting isosorbide dinitrate
Number of subjects: 18
Study: 7091638

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg domperidone
Number of subjects: 2

Group type: COMPARATOR
Intervention: No prophylactic antiemetic medication (control group)
Number of subjects: 2
Study: 30892124

Group type: EXPERIMENTAL
Intervention: BhCG days 1-4 follow-up protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BhCG days 1-7 follow-up protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: BhCG day 4-7 follow-up protocol
Number of subjects: 0
Study: 27875287

Group type: COMPARATOR
Intervention: Standard-dose AAs (2.4 g/[kg·d]) and SOY (n = 24)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard-dose AAs (2.4 g/[kg·d]) and MIX (n = 25)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High-dose AAs (3.6 g/[kg·d]) and SOY (n = 24)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High-dose AAs (3.6 g/[kg·d]) and MIX (n = 23)
Number of subjects: 142
Study: 26995372

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25256185

Group type: EXPERIMENTAL
Intervention: Retirement Village Physical Activity and Nutrition for Seniors (RVPANS) programme, a home-based physical activity and nutrition programme with educational resources and facilitators for 6 months.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (standard care or no intervention).
Number of subjects: 400
Study: 22743591

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20586755

Group type: EXPERIMENTAL
Intervention: Alcohol-cue exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control-cue exposure (sniffed water)
Number of subjects: 20
Study: 17494885

Group type: EXPERIMENTAL
Intervention: Uptitration of benazepril (median 20 mg/d; range 10 to 40)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Uptitration of losartan (median 100 mg/d; range 50 to 200)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional dosage of benazepril (10 mg/d)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional dosage of losartan (50 mg/d)
Number of subjects: 360
Study: 16334026

Group type: EXPERIMENTAL
Intervention: Conventional Pap smear
Number of subjects: 12107

Group type: EXPERIMENTAL
Intervention: Autocyte PREP (LBC)
Number of subjects: 12107

Group type: EXPERIMENTAL
Intervention: DNA‐Citoliq (LBC)
Number of subjects: 12107

Group type: COMPARATOR
Intervention: Hybrid Capture II (HCII)
Number of subjects: 12107
Study: 11804989

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning with a 120-second coronary occlusion
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nicorandil (an agonist of K(ATP) channels)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Glibenclamide (an antagonist of K(ATP) channels)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ischemic period lengthened to 180 seconds
Number of subjects: 56
Study: 9935014

Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (1 to 3 times the upper normal limit)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (3 to 5 times normal)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (5 to 10 times normal)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (>10 times normal)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Elevated CK-MB levels (any elevation)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Elevated total CK levels (above three times normal)
Number of subjects: 3535
Study: 8678248

Group type: EXPERIMENTAL
Intervention: Macintosh blade
Number of subjects: 20

Group type: COMPARATOR
Intervention: McCoy blade
Number of subjects: 20
Study: 2348469

Group type: EXPERIMENTAL
Intervention: Circadian rhythm-modulated rate (schedule B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Constant rate (schedule A)
Number of subjects: 23
Study: 103358

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg x 3-4 per day, starting 1-2 days before menstruation
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg x 3-4 per day, starting on the first day of bleeding
Number of subjects: 95

Group type: COMPARATOR
Intervention: Naproxen-sodium (double-blind crossover)
Number of subjects: 95
Study: 31959202

Group type: EXPERIMENTAL
Intervention: BCAA-based supplement (13.2g carbohydrates; 3.2g BCAA; 1.6g L-alanine per dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BCAA-based supplement
Number of subjects: 32
Study: 31016887

Group type: EXPERIMENTAL
Intervention: Muscle activating measures (neuromuscular electrical stimulation or whole-body vibration) in addition to early protocol-based physiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Early protocol-based physiotherapy alone (control)
Number of subjects: 50
Study: 28611274

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 9
Study: 24989842

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (14,000 units once weekly for 6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23414658

Group type: EXPERIMENTAL
Intervention: 20-hour communication skills course
Number of subjects: 62
Study: 22164761

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Lentinex for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Lentinex
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lentinex
Number of subjects: 42
Study: 19673020

Group type: EXPERIMENTAL
Intervention: Split dose midazolam in combination with meperidine (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single dose midazolam in combination with meperidine (Group B)
Number of subjects: 80
Study: 16771948

Group type: EXPERIMENTAL
Intervention: Standard dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standard dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standard dose pegylated interferon alpha-2b + ribavirin for genotype 1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low dose pegylated interferon alpha-2b + ribavirin for genotype 1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Doses exceeding the 1-2-5 threshold for genotype 1
Number of subjects: 50
Study: 15596921

Group type: EXPERIMENTAL
Intervention: Postoperative whole brain radiotherapy (WBRT) (n = 49 patients)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No further brain treatment (n = 46 patients)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Postoperative whole brain radiotherapy (WBRT)
Number of subjects: 95
Study: 12161766

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 9848882

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol and 2.5 mg medroxyprogesterone (n=7)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol alone (n=8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 23
Study: 8119527

Group type: EXPERIMENTAL
Intervention: Proximal duodenal distention (10, 20, 30 mL of air) during fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Distal duodenal distention (10, 20, 30 mL of air) during fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Proximal duodenal distention (10, 20, 30 mL of air) postprandially
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Distal duodenal distention (10, 20, 30 mL of air) postprandially
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both proximal and distal duodenal distention during fasting and postprandially
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Proximal duodenal distention during fasting
Number of subjects: 12
Study: 2680866

Group type: EXPERIMENTAL
Intervention: alpha-interferon therapy (90 million units per m2 total dose over 12 weeks)
Number of subjects: 114
Study: 336652

Group type: EXPERIMENTAL
Intervention: 100 mg pentobarbital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg methyprylon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg glutethimide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30913347

Group type: EXPERIMENTAL
Intervention: Negative trauma-related cognitions
Number of subjects: 137
Study: 28661970

Group type: EXPERIMENTAL
Intervention: Shenfu injection + postresuscitation care bundle
Number of subjects: 978

Group type: COMPARATOR
Intervention: Postresuscitation care bundle
Number of subjects: 978
Study: 25534960

Group type: EXPERIMENTAL
Intervention: High nitrate beverage
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low nitrate beverage
Number of subjects: 11
Study: 22782737

Group type: EXPERIMENTAL
Intervention: Brief intervention for smoking cessation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 21830957

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg daily)
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 14264
Study: 19804594

Group type: EXPERIMENTAL
Intervention: Topical nicotinamide (0.2% or 5%)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 4
Study: 16735702

Group type: EXPERIMENTAL
Intervention: Induction therapy containing one course with standard dose and one course with high-dose cytarabine
Number of subjects: 1770

Group type: COMPARATOR
Intervention: Induction therapy containing two courses with high-dose cytarabine
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Postremission therapy by prolonged maintenance
Number of subjects: 1770

Group type: COMPARATOR
Intervention: Postremission therapy by busulfan/cyclophosphamide chemotherapy with autologous stem-cell transplantation
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Induction therapy and postremission therapy
Number of subjects: 1770
Study: 15556150

Group type: EXPERIMENTAL
Intervention: Carbocysteine lysine salt monohydrate (SCMC-Lys) for 6 months
Number of subjects: 55
Study: 11292473

Group type: EXPERIMENTAL
Intervention: Outpatient group (self-administered misoprostol)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Inpatient group (administered misoprostol in hospital)
Number of subjects: 87